A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Bone Metastases
Interventions: BIOLOGICAL: Denosumab|DRUG: Zoledronic Acid
Sponsor: Amgen
Collaborators: Daiichi Sankyo